Group 1 - Collegium Pharmaceutical Inc. has entered into an agreement with Corium Therapeutics Holdings for the acquisition of AZSTARYS, involving $650 million in cash payments and potential earn-out considerations of up to $135 million [1][2] - The acquisition is expected to diversify the company's revenue streams beyond pain medicines and strengthen its position in the ADHD market, contributing to revenue through the late 2030s [2] - Collegium's existing operational and marketing capabilities in ADHD are anticipated to enhance margins and increase operating leverage following the acquisition [2] Group 2 - Collegium Pharmaceutical Inc. has been named an official partner of Boston Legacy FC, establishing a multi-year partnership aimed at improving fan experience during home games [3] - The partnership includes the creation of the Collegium Sensory Room at Gillette, Centreville, and White Stadium, designed to provide a peaceful environment for fans during matches [4] - This initiative aims to enhance the overall experience for visitors by offering a safer and more comfortable setting away from the intense match environment [4] Group 3 - Collegium Pharmaceutical Inc. specializes in the development and commercialization of pain management medicines, offering a diverse product range including Jornay PM, Belbuca, Xtampza ER, Nucynta ER, Nucynta IR, and Symproic [5]

Summary of Collegium Pharmaceutical Investor Call Company Overview - **Company**: Collegium Pharmaceutical (NasdaqGS:COLL) - **Event**: Investor Call regarding the acquisition of AZSTARYS from Corium Therapeutics - **Date**: March 19, 2026 Key Points Acquisition Details - Collegium announced the acquisition of AZSTARYS and relevant subsidiaries from Corium Therapeutics for **$650 million** in cash, with potential contingent payments of up to **$135 million** based on sales and regulatory milestones [8][10][19] - The acquisition is expected to close in the **second quarter of 2026** [19] Strategic Rationale - The acquisition significantly expands Collegium's position in the **ADHD** market, adding a second differentiated treatment alongside **Jornay PM** [5][19] - AZSTARYS is expected to extend ADHD revenues into **2037**, five years beyond Jornay PM's expected loss of exclusivity [7][19] - The deal is aligned with Collegium's capital allocation strategy, balancing portfolio expansion and fiscal responsibility [8][19] Financial Impact - The acquisition is projected to be immediately accretive to adjusted EBITDA, with AZSTARYS expected to generate over **$50 million** in pro forma net revenues in the second half of **2026** [10][11] - Collegium generated over **$329 million** in cash from operations in **2025**, indicating strong cash flow to support the acquisition [9] Market Context - The ADHD market is large and growing, with approximately **22 million** patients in the U.S. and **111 million** prescriptions written in **2025** [12] - ADHD prescriptions have been growing at about **8% annually** over the past five years, with **90%** of prescriptions for stimulant medications [12] Product Differentiation - Jornay PM is unique as it is taken at night and provides efficacy upon awakening, while AZSTARYS combines fast and long-acting medications in one capsule [15][17] - Both products target different patient needs, with Jornay PM primarily used in children and adolescents, and AZSTARYS having a more balanced distribution between adults and children [17][18] Sales and Marketing Strategy - Collegium plans to leverage its existing ADHD commercial infrastructure to drive growth for both products, expecting significant cost synergies of over **$50 million** within 12 months post-acquisition [10][19] - The company has a sales force of **180 representatives**, compared to Corium's **100**, which will enhance marketing efforts for AZSTARYS [30][37] Future Outlook - Collegium remains open to further acquisitions in both ADHD and potentially other therapeutic areas, maintaining a focus on capital-efficient opportunities [50][51] - The company aims to maximize the potential of both Jornay PM and AZSTARYS, ensuring broad access and support for the ADHD community [45][54] Additional Insights - Healthcare professionals have rated both Jornay PM and AZSTARYS highly, with **70%** indicating a strong intent to increase prescribing of Jornay PM and **53%** for AZSTARYS [15][16] - The acquisition reflects Collegium's commitment to innovation and financial discipline, aiming to create long-term shareholder value [19][21] Conclusion - The acquisition of AZSTARYS is a strategic move for Collegium, enhancing its ADHD portfolio and positioning the company for sustained growth and shareholder value creation in the biopharmaceutical sector [21][64]

Summary of Collegium Pharmaceutical Investor Call Company Overview - **Company**: Collegium Pharmaceutical (NasdaqGS: COLL) - **Industry**: Biopharmaceuticals, specifically focusing on ADHD and pain management Key Points from the Call Acquisition Announcement - Collegium announced the acquisition of **AZSTARYS** and relevant corporate subsidiaries from **Corium Therapeutics** for **$650 million** in cash, with potential contingent payments of up to **$135 million** based on sales and regulatory milestones [2][8][19] - This acquisition significantly expands Collegium's position in the ADHD market, complementing its existing product **Jornay PM** [2][5] Strategic Rationale - The acquisition is seen as a strategic addition that accelerates growth and enhances patient care, with a focus on differentiated commercial medicines that have exclusivity into the **2030s** and beyond [4][5] - AZSTARYS is expected to extend future ADHD revenues into **2037**, five years beyond Jornay PM's expected loss of exclusivity [7][19] Financial Implications - The acquisition is expected to be immediately accretive to adjusted EBITDA, with AZSTARYS projected to generate over **$50 million** in pro forma net revenues in the second half of **2026** [10][11] - Collegium generated over **$329 million** in cash from operations in **2025**, indicating strong cash flow to support the acquisition [9] Market Dynamics - The ADHD market is large and growing, with approximately **22 million** patients in the U.S. and **111 million** prescriptions written in **2025** [12] - Prescriptions for ADHD have been growing at about **8%** annually over the past five years, with **90%** of prescriptions for stimulant medications [12] Product Differentiation - **Jornay PM** is unique as it is taken at night and provides efficacy upon awakening, while **AZSTARYS** combines fast and long-acting medications in one capsule, addressing different patient needs [15][17] - Both products are expected to be complementary, with **70%** of healthcare professionals indicating a strong intent to increase prescribing of Jornay PM and **53%** for AZSTARYS [15][16] Operational Synergies - Collegium plans to leverage its existing ADHD commercial infrastructure to achieve significant cost synergies, estimated to exceed **$50 million** within 12 months post-acquisition [10] - The combined sales force will enhance market access and operational efficiencies, allowing for better service to the ADHD community [18] Future Outlook - Collegium remains focused on executing its strategy of driving growth through business development, with an openness to exploring other therapeutic areas, including rare diseases [49][50] - The company plans to update its financial guidance for **2026** following the transaction's closure, expected in the second quarter [11][19] Additional Insights - The acquisition aligns with Collegium's capital allocation strategy, balancing portfolio expansion with fiscal responsibility [8] - The company emphasizes its commitment to improving patient care and delivering shareholder value through strategic acquisitions and operational efficiencies [21][22]

Core Viewpoint - Collegium Pharmaceutical plans to acquire the ADHD drug AZSTARYS and related subsidiaries from Corium Therapeutics for $650 million, aiming to enhance its ADHD product portfolio and revenue stability [1][2]. Transaction Terms and Timing - The acquisition will be funded through cash on hand and a $300 million delayed-draw term loan, with an expected interest rate of SOFR plus 325 basis points [2]. - The deal is anticipated to close in the second quarter of 2026, with updated financial guidance to be provided post-transaction [3]. Strategic Rationale - The acquisition is part of a strategic initiative to diversify beyond pain management and strengthen Collegium's position in the ADHD market, leveraging existing commercial infrastructure [4]. - By adding AZSTARYS, the company aims to extend its ADHD revenue stream into 2037, five years beyond the expected loss of exclusivity for Jornay PM [5]. Financial Expectations and Synergy Targets - The transaction is expected to be immediately accretive to adjusted EBITDA, with increased financial benefits anticipated starting in 2027 [6]. - Collegium reported over $329 million in cash from operations in 2025 and expects strong cash generation in the following years, with a projected net debt to adjusted EBITDA ratio of approximately 2x post-acquisition [6][7].

Core Insights - The company achieved record full-year net revenues of $780.6 million, representing a 24% increase driven by the first full year of Jornay PM ownership and continued growth in the core pain portfolio [1] - Jornay PM delivered 48% revenue growth compared to pro forma 2024, supported by a strong back-to-school season and the initial impact of sales force expansion from 125 to 180 representatives [1] - The pain portfolio, which includes Belbuca, Xtampza ER, and Nucynta, grew 6% year-over-year to $631.7 million, reinforcing management's view that these revenues are more durable than market expectations [1] Financial and Operational Highlights - The company successfully transitioned the Nucynta franchise to an authorized generic (AG) model with Hikma Pharmaceuticals, utilizing a profit-share structure to maintain value against third-party generic competition [1] - The balance sheet was strengthened by closing a $980 million syndicated credit facility, reducing interest costs and providing nearly $400 million in additional liquidity for future portfolio diversification [1] - Operational efficiency enabled the company to reach a net leverage ratio of less than 1 time, meeting an ambitious deleveraging target set earlier in the year [1]

Core Insights - Collegium Pharmaceutical reported revenue of $205.45 million for the quarter ended December 2025, reflecting a year-over-year increase of 12.9% [1] - The earnings per share (EPS) for the quarter was $2.04, up from $1.77 in the same quarter last year, but below the consensus estimate of $2.19, resulting in an EPS surprise of -6.99% [1] - The revenue fell short of the Zacks Consensus Estimate of $208.65 million, leading to a revenue surprise of -1.53% [1] Revenue Breakdown - Total product revenues for Belbuca reached $59.14 million, exceeding the three-analyst average estimate of $58.03 million, with a year-over-year change of +7.1% [4] - Xtampza ER generated $48.58 million in product revenues, which was below the average estimate of $51.37 million, showing a year-over-year decline of -5.6% [4] - Symproic reported revenues of $3.89 million, surpassing the average estimate of $3.53 million, but reflecting a year-over-year decrease of -8.6% [4] - Nucynta achieved $47.95 million in revenues, slightly below the average estimate of $49.47 million, with a year-over-year increase of +14.8% [4] - Jornay PM's revenues were $45.89 million, close to the average estimate of $46.46 million [4] Stock Performance - Collegium Pharmaceutical's shares have returned +2.1% over the past month, outperforming the Zacks S&P 500 composite, which changed by +0.6% [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating expected performance in line with the broader market in the near term [3]

Core Insights - Collegium Pharmaceutical reported record financial results for the fourth quarter and full year 2025, driven by growth in its ADHD product Jornay PM and steady performance across its pain portfolio [5][3][4]. Financial Performance - Full-year 2025 net revenues reached a record $780.6 million, with adjusted EBITDA at a record $460.5 million [3]. - Fourth-quarter net product revenues were $205.4 million, up 13% year-over-year, and adjusted EBITDA was $127.3 million, up 18% year-over-year [3]. - The company generated over $329 million in cash from operations and ended 2025 with over $386 million in cash, an increase of approximately $224 million from the end of 2024 [4]. Product Performance - Jornay PM, an evening-dosed ADHD stimulant, was a key growth driver, with over 200,000 prescriptions written in Q4 2025, a 16% increase year-over-year, and more than 760,000 prescriptions for the full year, up 20% [1][2]. - The total prescriber base for Jornay PM reached over 29,000 in Q4, a 21% increase year-over-year, with market share in the long-acting branded methylphenidate market growing to nearly 26%, up 6.5 percentage points year-over-year [6]. Strategic Initiatives - Management emphasized three strategic priorities: expanding Jornay PM, maximizing the durability of the pain franchise, and deploying capital to enhance shareholder value [5]. - Collegium secured new formulary coverage under a major commercial healthcare plan effective May 1, which is expected to increase Jornay's coverage by approximately 4.5 million covered lives [8]. Pain Portfolio - The pain portfolio generated $631.7 million in revenue for 2025, up 6% year-over-year, with all three core pain medicines delivering full-year growth [9]. - Specific product revenues included Belbuca at $59.1 million in Q4 (+7% YoY) and $221.7 million for 2025 (+5% YoY), Xtampza ER at $48.6 million in Q4 (-6% YoY) and $199.3 million for 2025 (+4% YoY), and Nucynta franchise at $47.9 million in Q4 (+15% YoY) and $196.3 million for 2025 (+11% YoY) [10][11]. 2026 Outlook - For 2026, the company expects total product revenues of $805 million to $825 million, representing a 4% year-over-year increase, and adjusted EBITDA of $455 million to $475 million [14]. - Jornay's revenue is projected to be between $190 million and $200 million, indicating a 31% growth year-over-year [15]. Capital Deployment - Collegium closed a $980 million syndicated credit facility in December 2025, which is expected to drive meaningful annualized interest savings and provide flexibility for potential acquisitions [17]. - The company repurchased $25 million of shares in 2025 and has $150 million remaining under its board-authorized repurchase program through December 31, 2026 [18].

Financial Data and Key Metrics Changes - In 2025, the company achieved record net revenues of $780.6 million, representing a 24% year-over-year increase, and adjusted EBITDA of $460.5 million, up 15% year-over-year [25][31] - The company generated over $329 million in cash from operations in 2025 and ended the year with over $386 million in cash, an increase of approximately $224 million from the end of 2024 [7][31] - GAAP net income for the quarter was $17 million, up 36% year-over-year, while full-year GAAP net income was $62.9 million, down 9% year-over-year due to a one-time loss on extinguishment of debt [29][30] Business Line Data and Key Metrics Changes - Jornay PM net revenue was $45.9 million in Q4, up 57% year-over-year, and $148.9 million for the full year, up 48% compared to pro forma 2024 revenue [26][31] - The pain portfolio generated $631.7 million in 2025, up 6% year-over-year, with all three core pain medicines delivering full-year growth [7][21] - Belbuca net revenue was $59.1 million in Q4, up 7% year-over-year, and $221.7 million in 2025, up 5% year-over-year [26][27] Market Data and Key Metrics Changes - Jornay's market share of the long-acting branded methylphenidate market grew to nearly 26% in Q4, up 6.5 percentage points year-over-year [18] - The pediatric and adolescent segment, which represents about 80% of total prescriptions, grew 14% year-over-year, while the adult segment grew 24% year-over-year [18][19] - The prescriber base for Jornay PM reached an all-time high of over 29,000 in Q4, up 21% year-over-year [18] Company Strategy and Development Direction - The company focuses on three strategic priorities: driving growth for Jornay PM, maximizing the durability of the pain portfolio, and strategically deploying capital to enhance shareholder value [4][10] - The company aims to expand its portfolio through business development while maintaining a strong balance sheet, as evidenced by the closing of a $980 million syndicated credit facility [8][34] - The company is committed to maximizing the life cycle of its pain portfolio and ensuring accessibility to its medicines [9][21] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to drive growth in 2026, expecting Jornay revenue to be in the range of $190 million-$200 million, representing over 30% annual growth [11][32] - The company anticipates a modest quarter-over-quarter decline in revenues in Q1 2026 due to typical seasonal dynamics, but remains optimistic about long-term growth [32][33] - Management highlighted the importance of ongoing investments in sales and marketing to support future growth, particularly for Jornay PM [10][11] Other Important Information - The company published its 2025 ESG report, emphasizing its commitment to social responsibility alongside financial performance [5][6] - The company repurchased $25 million in shares through its share repurchase program, reinforcing its capital deployment strategy [8][34] Q&A Session Questions and Answers Question: What assumptions underlie 2026 Jornay guidance, and how should we think about factors that could lead to upside? - Management indicated that growth is expected to be driven by demand growth, with relative stability in gross to nets between 2025 and 2026 [40] Question: Have there been any competitive developments in the ADHD market that could potentially impact Jornay demand? - Management noted that there have not been any material changes in competitive dynamics that could impact Jornay demand, emphasizing its differentiated delivery technology [41] Question: Can you help us frame how you're thinking about the ramp to peak for Jornay? - Management stated that they have not previously discussed peak sales but expect to see the impact of expanded sales and marketing efforts throughout 2026 [45] Question: How promotionally sensitive are Belbuca and Xtampza at this stage of their life cycle? - Management indicated that Belbuca and Xtampza are promotionally sensitive, and the sales team is focused on navigating the complex payer environment [47] Question: How are you thinking about acquiring a rare disease-focused asset? - Management expressed interest in rare disease assets but emphasized a preference for commercial or near-commercial assets that align with existing therapeutic areas [51][54]

Financial Data and Key Metrics Changes - In 2025, the company achieved record net revenues of $780.6 million, representing a 24% year-over-year increase, and adjusted EBITDA of $460.5 million, up 15% year-over-year [25][31] - The company generated over $329 million in cash from operations in 2025 and ended the year with over $386 million in cash, an increase of approximately $224 million from the end of 2024 [7][31] - GAAP net income for the fourth quarter was $17 million, up 36% year-over-year, while full-year GAAP net income was $62.9 million, down 9% year-over-year due to a one-time loss on extinguishment of debt [29][30] Business Line Data and Key Metrics Changes - Jornay PM prescriptions grew by 20% year-over-year, generating $148.9 million in net revenue, up 48% compared to pro forma 2024 revenue [6][26] - The pain portfolio generated $631.7 million in 2025, up 6% year-over-year, with all three core pain medicines delivering full-year growth [7][21] - Belbuca net revenue was $221.7 million in 2025, up 5% year-over-year, while Xtampza ER net revenue was $199.3 million, up 4% year-over-year [26][27] Market Data and Key Metrics Changes - Jornay's market share of the long-acting branded methylphenidate market grew to nearly 26% in the fourth quarter, up 6.5 percentage points year-over-year [18] - The pediatric and adolescent segment, which represents about 80% of total prescriptions, grew 14% year-over-year, while the adult segment grew 24% year-over-year [18][19] - The company secured new formulary access under a major commercial healthcare plan, increasing Jornay's coverage by an estimated 4.5 million covered lives [21] Company Strategy and Development Direction - The company focuses on three strategic priorities: driving growth for Jornay PM, maximizing the durability of the pain portfolio, and strategically deploying capital to enhance shareholder value [4][10] - The company aims to expand and diversify its portfolio through business development, debt repayment, and opportunistic share repurchases [11][33] - The company is committed to maximizing the life cycle of its pain portfolio and ensuring medicines remain accessible to patients [9][21] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to deliver near and long-term growth, emphasizing the strong financial foundation provided by the pain portfolio and the growth potential of Jornay [12][37] - The company expects total product revenues in 2026 to be in the range of $805 million to $825 million, reflecting a 4% increase year-over-year driven by Jornay growth and durable revenues from the pain portfolio [31][32] - Management noted that they do not foresee significant competitive developments that could impact Jornay demand, highlighting its differentiated delivery technology [41] Other Important Information - The company published its 2025 ESG report, showcasing its commitment to social responsibility alongside financial success [5] - The company closed a $980 million syndicated credit facility, improving interest rates and providing flexibility for future business development opportunities [8][34] Q&A Session Questions and Answers Question: What assumptions underlie 2026 Jornay guidance, and how should we think about factors that could lead to upside? - Management indicated that growth is expected to be driven by demand growth, with relative stability in gross to nets between 2025 and 2026 [40] Question: Have there been any competitive developments in the ADHD market that could potentially impact Jornay demand? - Management stated that they do not see any material changes in competitive dynamics that could impact Jornay demand, emphasizing its unique delivery technology [41] Question: Can you help us frame how you're thinking about the ramp to peak sales for Jornay? - Management noted that they have not previously discussed peak sales but expect to see the impact of expanded sales and marketing activities throughout 2026 [45] Question: How promotionally sensitive are Belbuca and Xtampza at this stage of their life cycle? - Management indicated that Belbuca and Xtampza are highly promotionally sensitive, and they will continue to invest in these products [47][48]

Financial Data and Key Metrics Changes - In 2025, the company achieved record net revenues of $780.6 million, representing a 24% year-over-year increase, and adjusted EBITDA of $460.5 million, up 15% year-over-year [26][32] - The company generated robust operating cash flows of $329.3 million and ended the year with $386.7 million in cash equivalents and marketable securities, an increase of approximately $224 million from the end of 2024 [7][32] - GAAP net income for the fourth quarter was $17 million, up 36% year-over-year, while full-year GAAP net income was $62.9 million, down 9% year-over-year due to a one-time loss on extinguishment of debt [29][30] Business Line Data and Key Metrics Changes - Jornay PM net revenue reached $148.9 million in 2025, up 48% compared to pro forma 2024 revenue, with prescriptions growing by 20% year-over-year [6][27] - The pain portfolio generated $631.7 million in 2025, reflecting a 6% year-over-year growth, with all three core pain medicines showing full-year growth [7][22] - Belbuca net revenue was $221.7 million in 2025, up 5% year-over-year, while Xtampza ER net revenue was $199.3 million, up 4% year-over-year [27] Market Data and Key Metrics Changes - Jornay's market share in the long-acting branded methylphenidate market grew to nearly 26% in the fourth quarter, up 6.5 percentage points year-over-year [19] - The pediatric and adolescent segment, which represents about 80% of total prescriptions, grew 14% year-over-year, while the adult segment grew 24% year-over-year [19][20] - The prescriber base for Jornay reached an all-time high of over 29,000, up 21% year-over-year [19] Company Strategy and Development Direction - The company focuses on three strategic priorities: driving growth for Jornay PM, maximizing the durability of the pain portfolio, and disciplined capital deployment to enhance shareholder value [4][11] - The company aims to expand its portfolio through business development, targeting assets that are commercial or near-commercial with a focus on neuropsychiatry, pediatrics, and pain [36] - The company has made significant investments in sales and marketing to support Jornay's growth, including expanding the sales force and launching new marketing campaigns [12][21] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to drive growth in 2026, expecting Jornay revenue to be in the range of $190 million-$200 million, representing over 30% annual growth [12][33] - The company anticipates a modest quarter-over-quarter decline in revenues in Q1 2026 due to typical seasonal dynamics, but remains optimistic about long-term growth prospects [34] - Management highlighted the importance of maintaining broad payer access for Jornay and securing formulary access under a major commercial healthcare plan [22] Other Important Information - The company published its 2025 ESG report, emphasizing its commitment to social responsibility alongside financial success [5] - The company closed a $980 million syndicated credit facility, improving its interest rate and debt terms, which provides additional flexibility for future business development opportunities [9][35] Q&A Session Summary Question: What assumptions underlie 2026 Jornay guidance, and how should we think about factors that could lead to upside? - Management indicated that growth is expected to be driven by demand growth, with relative stability in gross to nets between 2025 and 2026 [40] Question: Have there been any competitive developments in the ADHD market that could potentially impact Jornay demand? - Management noted that there have not been any material changes in competitive dynamics or future launches that could impact Jornay demand, emphasizing its differentiation in the market [41] Question: Can you help us frame how you're thinking about the ramp to peak sales for Jornay? - Management stated that they have not previously discussed peak sales but expect to see the impact of expanded sales and marketing activities throughout 2026 [44] Question: How promotionally sensitive are Belbuca and Xtampza at this stage of their life cycle? - Management indicated that Belbuca and Xtampza are highly promotionally sensitive, and the sales team is focused on navigating the complex payer environment [47]